Among the 11,568 patients diagnosed with metastatic diseases at distant sites analyzed for incidence, 51.8%, 13.2%, 6.9%, 11.1%, and 17.0% had HR+/HER2−, HR+/HER2+, HR−/HER2+, triple‐negative, and unknown subtypes, respectively. Here, ERBB2 is linked to metastatic neoplasm.